Summary
Inorevia is a spin-off from the Institut Curie/CNRS (Paris) that leverages over ten years of research in microfluidics to tackle challenges of modern Biology and Medicine with faster, cheaper, miniaturised sample preparation. Inorevia’s ground-breaking biology platform, the MAGELIA, will provide Biologists and Clinicians with a unique tool to efficiently process raw biological samples upstream of advanced analysis methods such as Next-Generation Sequencing (NGS) in volumes 100 to 1000 times smaller, in an entirely automated platform.
After over 2 years of R&D and a first TRL6 prototype of the MAGELIA platform, Inorevia is ready to accelerate its development to reach TRL8, finish the development of the MAGELIA and initiate its commercialization by 2021. Aiming for the NGS sample preparation market, this first generation of the MAGELIA platform will meet the needs of low to medium throughput labs, sequencing platforms, biotech and pharmacy companies, who struggle with low-reproducibility manual library preparations, expensive reagents, and scarce biological samples. The MAGELIA platform will democratise NGS to ignite a revolution in genomics on a fast-growing 8 Billion € market.
To succeed, Inorevia has put together an 8 persons’ team of recognized scientists, engineers, and confirmed business talents, backed by a renowned advisory board. The company holds exclusive rights on 4 key patents and large know-how. Since its inception in 2016, Inorevia has won several renowned awards in France and Europe, secured over 1.3 M€ in grants and a seed round.
The MAGELIA SME Instrument Phase 2 project specifically aims at accelerating Inorevia’s go-to market through faster development, earlier pre-series and larger market reach in Europe. With the objective to reach over 400 customers and 15% of the European market within five years, with a turnover of 30 M€, INOREVIA will become the European leader in miniaturized samples preparation for modern biology and medicine.
After over 2 years of R&D and a first TRL6 prototype of the MAGELIA platform, Inorevia is ready to accelerate its development to reach TRL8, finish the development of the MAGELIA and initiate its commercialization by 2021. Aiming for the NGS sample preparation market, this first generation of the MAGELIA platform will meet the needs of low to medium throughput labs, sequencing platforms, biotech and pharmacy companies, who struggle with low-reproducibility manual library preparations, expensive reagents, and scarce biological samples. The MAGELIA platform will democratise NGS to ignite a revolution in genomics on a fast-growing 8 Billion € market.
To succeed, Inorevia has put together an 8 persons’ team of recognized scientists, engineers, and confirmed business talents, backed by a renowned advisory board. The company holds exclusive rights on 4 key patents and large know-how. Since its inception in 2016, Inorevia has won several renowned awards in France and Europe, secured over 1.3 M€ in grants and a seed round.
The MAGELIA SME Instrument Phase 2 project specifically aims at accelerating Inorevia’s go-to market through faster development, earlier pre-series and larger market reach in Europe. With the objective to reach over 400 customers and 15% of the European market within five years, with a turnover of 30 M€, INOREVIA will become the European leader in miniaturized samples preparation for modern biology and medicine.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/873262 |
| Start date: | 01-08-2019 |
| End date: | 30-09-2021 |
| Total budget - Public funding: | 2 793 000,00 Euro - 1 955 100,00 Euro |
Cordis data
Original description
Inorevia is a spin-off from the Institut Curie/CNRS (Paris) that leverages over ten years of research in microfluidics to tackle challenges of modern Biology and Medicine with faster, cheaper, miniaturised sample preparation. Inorevia’s ground-breaking biology platform, the MAGELIA, will provide Biologists and Clinicians with a unique tool to efficiently process raw biological samples upstream of advanced analysis methods such as Next-Generation Sequencing (NGS) in volumes 100 to 1000 times smaller, in an entirely automated platform.After over 2 years of R&D and a first TRL6 prototype of the MAGELIA platform, Inorevia is ready to accelerate its development to reach TRL8, finish the development of the MAGELIA and initiate its commercialization by 2021. Aiming for the NGS sample preparation market, this first generation of the MAGELIA platform will meet the needs of low to medium throughput labs, sequencing platforms, biotech and pharmacy companies, who struggle with low-reproducibility manual library preparations, expensive reagents, and scarce biological samples. The MAGELIA platform will democratise NGS to ignite a revolution in genomics on a fast-growing 8 Billion € market.
To succeed, Inorevia has put together an 8 persons’ team of recognized scientists, engineers, and confirmed business talents, backed by a renowned advisory board. The company holds exclusive rights on 4 key patents and large know-how. Since its inception in 2016, Inorevia has won several renowned awards in France and Europe, secured over 1.3 M€ in grants and a seed round.
The MAGELIA SME Instrument Phase 2 project specifically aims at accelerating Inorevia’s go-to market through faster development, earlier pre-series and larger market reach in Europe. With the objective to reach over 400 customers and 15% of the European market within five years, with a turnover of 30 M€, INOREVIA will become the European leader in miniaturized samples preparation for modern biology and medicine.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
